<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-T5N4X6G" height="0" width="0" style="display:none;visibility:hidden">

SmartTRAK Life Sciences News and Analysis Blog

1 min read

Bioventus CEO cites SmartTRAK HA Market Stats in Durolane Approval

9/10/17 9:00 AM

Durham-based Bioventus has received approval from the U.S. Food and Drug Administration for its treatment, Durolane.

The single-injection product treats knee osteoarthritis pain. The company plans to launch Durolane in the U.S. early next year.

Citing BioMedGPS SmartTRAK, Bioventus CEO Tony Bihl said in an email that “the 2016 entire HA market in the US (1-shot, 2-shot, 3-shot and 5-shot) was about $979 million.”

Durham-based Bioventus CEO Tony BihlDurham-based Bioventus CEO Tony Bihl

Read the story by Jennifer Henderson at Triangle Business Journal...

Read the Bioventus Press Release Bioventus Receives US FDA Approval for DUROLANE®.

Topics: Orthopedics

Rebecca Gonzalez
Written by Rebecca Gonzalez

Rebecca is our Digital Marketing Maven.

    Recent Articles